PositoAI/ US/ Rallybio Corporation

Rallybio Corporation

NasdaqCM: RLYB · Healthcare

Positivity Index

#2,122 / 6,774

Global

#595 / 4,000

United States

Positivity Score

21,867

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Rallybio Corporation — Overview & Financial Snapshot

Rallybio Corporation (NasdaqCM: RLYB) is a Healthcare company, ranked #2,122 of 6,774 companies globally and #595 of 4,000 in United States on PositoAI, with a Positivity Score of 21,867. Its market capitalisation is ₹822.39 Cr ($87.13M), P/E ratio is 2.0 and P/B ratio is 0.92. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

P/B Ratio 0.92

P/E Ratio 2.0

D/E Ratio 0.00

ROE 64.86%

Owes vs Owns ? 0.04× Low $0.04 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹756.07$8.01

Forward EPS ₹-509.71$-5.40

Beta -0.71

Market Cap ₹822.39 Cr$87.13M

What these numbers mean →

What does Rallybio Corporation do?

What is Rallybio Corporation's P/E and P/B ratio?

Rallybio Corporation has a P/E ratio of 2.0 and a P/B ratio of 0.92.

What is Rallybio Corporation's debt-to-equity ratio?

Rallybio Corporation has a debt-to-equity ratio of 0.00.

How much does Rallybio Corporation owe compared with what it owns?

Rallybio Corporation owes $0.04 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Rallybio Corporation's Positivity rank?

Rallybio Corporation is ranked #2,122 of 6,774 companies globally and #595 of 4,000 in United States on PositoAI, with a Positivity Score of 21,867.

Does Rallybio Corporation have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Rallybio Corporation.

Where can I read the latest news about Rallybio Corporation?

Recent headlines about Rallybio Corporation from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Rallybio Corporation have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Rallybio Corporation's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.